Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.
Standard
Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. / Petersen, Jörg; Dandri-Petersen, Maura; Mier, Walter; Lütgehetmann, Marc; Volz, Tassilo; von Weizsäcker, Fritz; Haberkorn, Uwe; Fischer, Lutz; Pollok, Jörg-Matthias; Erbes, Berit; Seitz, Stefan; Urban, Stephan.
In: NAT BIOTECHNOL, Vol. 26, No. 3, 3, 2008, p. 335-341.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.
AU - Petersen, Jörg
AU - Dandri-Petersen, Maura
AU - Mier, Walter
AU - Lütgehetmann, Marc
AU - Volz, Tassilo
AU - von Weizsäcker, Fritz
AU - Haberkorn, Uwe
AU - Fischer, Lutz
AU - Pollok, Jörg-Matthias
AU - Erbes, Berit
AU - Seitz, Stefan
AU - Urban, Stephan
PY - 2008
Y1 - 2008
N2 - 360 million people are chronically infected with the human hepatitis B virus (HBV) and are consequently prone to develop liver cirrhosis and hepatocellular carcinoma. As approved therapeutic regimens-which modulate patients' antiviral defenses or inhibit the viral reverse transcriptase-are generally noncurative, strategies interfering with other HBV replication steps are required. Expanding on our demonstration that acylated peptides derived from the large HBV envelope protein block virus entry in vitro, we show their applicability to prevent HBV or woolly monkey hepatitis B virus infection in vivo, using immunodeficient urokinase-type plasminogen activator (uPA) mice repopulated with primary human or Tupaia belangeri hepatocytes. Accumulation of the peptides in the liver, their extraordinary inhibitory potency and specific mode of action permit subcutaneous delivery at very low doses. Inhibition of hepadnavirus entry thus constitutes a therapeutic approach to prevent primary HBV infection, such as after liver transplantation, and might also restrain virus spread in chronically infected patients.
AB - 360 million people are chronically infected with the human hepatitis B virus (HBV) and are consequently prone to develop liver cirrhosis and hepatocellular carcinoma. As approved therapeutic regimens-which modulate patients' antiviral defenses or inhibit the viral reverse transcriptase-are generally noncurative, strategies interfering with other HBV replication steps are required. Expanding on our demonstration that acylated peptides derived from the large HBV envelope protein block virus entry in vitro, we show their applicability to prevent HBV or woolly monkey hepatitis B virus infection in vivo, using immunodeficient urokinase-type plasminogen activator (uPA) mice repopulated with primary human or Tupaia belangeri hepatocytes. Accumulation of the peptides in the liver, their extraordinary inhibitory potency and specific mode of action permit subcutaneous delivery at very low doses. Inhibition of hepadnavirus entry thus constitutes a therapeutic approach to prevent primary HBV infection, such as after liver transplantation, and might also restrain virus spread in chronically infected patients.
M3 - SCORING: Zeitschriftenaufsatz
VL - 26
SP - 335
EP - 341
JO - NAT BIOTECHNOL
JF - NAT BIOTECHNOL
SN - 1087-0156
IS - 3
M1 - 3
ER -
